114mIn, a candidate for radionuclide therapy: low-energy cyclotron production and labeling of DTPA-D-Phe-octreotide

Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease

“…While numerous reports exist which involve the use of 110 In269,270 110m In271 and 114m In272, this review will focus on the production, purification, and radiopharmaceutical applications of 111 In, since it is the most widely used and extensively studied indium radiometal.…”

Radionuclide candidates for β+γ coincidence PET: An overview

“…However, as confirmed by in vivo clinical studies, it provides 3 times better resolution than the typical 111 In SPECT (Lubberink et al, 2002b) which opens the possibilities for the detection of small tumors with indium-labelled radiopharmaceuticals. This might be important in the light of an emerging radioisotope 114m In (IAEA, 2007), an Auger emitter with almost instant β-emissions (from its short-lived daughter), whose therapeutic properties are expected (Tolmachev et al, 2000). Additionally, 110m In emits medium-energy but high-intensity γ line which could be potentially interesting for β+γ coincidence PET.…”

External and internal radiation therapy: Past and future directions

“…211 At, [91] 212 Pb, 213 Bi and 225 Ac), [92] In-2IT-BAD-m170), 114m In, 123 I, 125 I, 99m Tc and 67 Ga). [66,[88][89][90][91][92][93][94][95] Peptid receptor radionuclide therapy Radionuclide therapy using radiolabelled peptides therefore holds great promise for the treatment of cancer, especially when used in conjunction with other therapy modalities or when combinations of, for example, different peptides or radionuclides are used. [96] On their plasma membranes, cells express receptor proteins with high affinity for regulatory peptides, such as somatostatin.…”